Insmed Inc Stock Price, News & Analysis

Insmed reported a robust third quarter for 2020, with total revenue reaching $43.6 million, a 12% increase from the previous year. U.S. net sales accounted for $42 million. The net loss was $63.7 million or $0.63 per share, slightly higher than the prior year. Key developments included ARIKAYCE's approval in the EU and expanded efficacy data from the FDA. Insmed also initiated a Phase 1 study for TPIP and planned a Phase 3 study for brensocatib. As of September 30, 2020, cash reserves stood at $588.8 million.

Insmed Incorporated (Nasdaq: INSM) announced that the European Commission has granted marketing authorization for ARIKAYCE® to treat nontuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium complex (MAC) in adults without cystic fibrosis. This approval follows the positive opinion from the EMA's Committee for Medicinal Products and is based on the Phase 3 CONVERT study, which showed ARIKAYCE improves sputum culture conversion rates. Insmed plans to launch ARIKAYCE in Germany and subsequently in other EU markets, supporting patients through tailored programs.

Insmed Incorporated (Nasdaq: INSM) announced the release of its third quarter 2020 financial results on October 29, 2020. A conference call for investors will take place at 8:30 a.m. ET to discuss these results. Interested participants can join by calling (833) 340-0284 domestically or (236) 712-2425 internationally and using conference ID number 8292364. A replay will be available two hours after the call until November 12, 2020. Insmed focuses on transforming lives through innovative therapies for rare diseases, including ARIKAYCE^® for MAC lung disease.

Insmed has announced the granting of inducement awards to nine new employees as part of their recruitment strategy, compliant with NASDAQ Listing Rule 5635(c)(4). Each employee received options to purchase a total of 42,320 shares at an exercise price of $33.25, the closing price on October 1, 2020. The options come with a ten-year term and a four-year vesting schedule, designed to retain talent in a competitive industry. Insmed focuses on advancing therapies for serious and rare diseases, including ARIKAYCE, brensocatib, and treprostinil palmitil.

Insmed Incorporated (Nasdaq: INSM) announced progress at its virtual R&D Day, highlighting its expanding portfolio aimed at treating serious and rare diseases. The company initiated a Phase 1 trial for Treprostinil Palmitil Inhalation Powder (TPIP) and plans to begin a Phase 2a study for pulmonary arterial hypertension in early 2021. Insmed aims to leverage its drug brensocatib to address neutrophil-mediated diseases, starting with a Phase 3 trial for non-cystic fibrosis bronchiectasis. The company also detailed global expansion efforts for its product ARIKAYCE, expecting EU marketing authorization by October 2020.

Insmed, a biopharmaceutical company, will host a virtual R&D Day on September 30, 2020, from 10:00 a.m. to 12:30 p.m. ET. The event will highlight updates on pipeline candidates, including treprostinil palmitil and brensocatib, as well as advancements for ARIKAYCE (amikacin liposome inhalation suspension). Dr. Ronald J. Oudiz will present during the event. The conference call will be accessible live and recorded for later viewing. Insmed focuses on serious and rare diseases with its innovative therapies.

Insmed Incorporated (Nasdaq:INSM) announced participation in three virtual investor conferences in September 2020. Management will present at the H.C. Wainwright Annual Global Investment Conference on September 14, 2020, Morgan Stanley Annual Global Healthcare Conference on September 15, 2020, and the Cantor Virtual Healthcare Conference on September 17, 2020. Each presentation will be streamed live, accessible on the company's investor relations webpage and archived for 30 days. Insmed focuses on treatments for serious rare diseases, including its product ARIKAYCE®.

Insmed announced the publication of final results from the Phase 2 WILLOW study for brensocatib, a treatment for non-cystic fibrosis bronchiectasis (NCFBE), in the New England Journal of Medicine. Findings showed significant improvement in time to first pulmonary exacerbation compared to placebo, with risk reductions of 42% and 38% for two dosages. The treatment was well tolerated, with manageable adverse events. Insmed aims to initiate a Phase 3 program for brensocatib by year-end 2020, highlighting the urgency for therapeutic options in NCFBE.

Insmed Incorporated (Nasdaq: INSM) announced the grant of inducement awards to 12 new employees as per NASDAQ Listing Rule 5635(c)(4). Approved by the Compensation Committee, these awards include options to purchase a total of 84,520 shares at an exercise price of $28.17 per share, which is the closing price on September 1, 2020. The options come with a ten-year term and a four-year vesting schedule, aimed at incentivizing employee retention and commitment to the company.